Radzio-Basu, Jessica
Council, Olivia
Cong, Mian-er
Ruone, Susan
Newton, Alicia
Wei, Xierong
Mitchell, James
Ellis, Shanon
Petropoulos, Christos J.
Huang, Wei
Spreen, William
Heneine, Walid
García-Lerma, J. Gerardo
Funding for this research was provided by:
CDC intramural funds
Article History
Received: 17 October 2018
Accepted: 19 February 2019
First Online: 1 May 2019
Competing interests
: J.G.G-L. and W.H. are named in US. Government patents describing the use of a nucleoside and a nucleotide reverse transcriptase inhibitor for PrEP (Inhibition of HIV infection through chemoprophylaxis, patents No. 9044509B2, 9579333, and 9937191), and on a patent application on “HIV Post-exposure Prophylaxis”. C.J.P. is a Corporate Officer (Vice President) and shareholder of Laboratory Corporation of America (LabCorp), and the Chief Scientific Officer of Monogram Biosciences, a member of the LabCorp Specialty Testing Group. Monogram Biosciences/LabCorp are for-profit providers of HIV drug resistance testing services that support routine diagnostic testing and the development of new antiviral drug candidates. We.H. and A.N. are employees and shareholders of Laboratory Corporation of America (LabCorp) and Monogram Biosciences. W.S. is an employee of ViiV Healthcare, the company who owns and is developing cabotegravir. The remaning authors declare no competing interests.